Videos

The Role of Maintenance Therapy in HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.

Discussing Treatment Decisions with Patients with Early-Stage HER2+ Breast Cancer

Dr Sarah M. Tolaney discusses whether maintenance therapy has a role in HER2+ breast cancer treatment.

Considerations for Patient-Focused, Shared Decision-Making in RCC

A key opinion leader explains how she discusses treatment options and trial data with patients with early stage HER2+ breast cancer.

David Aggen, MD, PhD;Arnab Basu, MD, MPH, FACP;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Patient-Specific Factors Impacting Treatment Choices in RCC

Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Uday R. Popat, MD, Reviews Post-Transplant Cyclophosphamide Vs Tacrolimus and Methotrexate to Prevent GVHD in AML/MDS

Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.

Uday R. Popat, MD

Case Presentation 1: Selecting Therapy in Transplant-Ineligible NDMM

Uday R. Popat, MD, spoke about how well post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease was performed in this trial.

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

May 17th 2022

Centering discussion on a patient case of transplant-ineligible newly diagnosed multiple myeloma, experts consider how they would approach workup and management.

NDMM Management: Assessing Response and Determining Duration of Therapy

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

May 17th 2022

Comprehensive insight on optimizing newly diagnosed multiple myeloma management, ranging from response assessment to use of consolidation and maintenance therapy.

ELEVATE-RR Study Overview

Michael R. Bishop, MD;Bruce B. Bank, MD

Introduction and CLL Background

Dr Bishop reviews the ELEVATE-RR trial enrollment strategy.

Michael R. Bishop, MD;Bruce B. Bank, MD

Clinical Case Presentation: A 66-Year-Old Woman with ER+ HER2+ Invasive Ductal Carcinoma and Brain Metastases

Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.

Sara Hurvitz, MD;Ruta Rao, MD;Stefania Maraka, MD

Novel Agents Under Evaluation for HER2+ Breast Cancer and Brain Metastases

Sara Hurvitz, MD, presents the case of a 66-year-old woman with ER+ HER2+ invasive ductal carcinoma and brain metastases.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer

A look at exciting clinical trials enrolling patients with HER2+ breast cancer and leptomeningeal disease, a previously unheard-of opportunity.

David O'Malley, MD, The Ohio State University Comprehensive Cancer Center

IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCLC

David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

CheckMate-816: Neoadjuvant Chemoimmunotherapy for NSCLC

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD

HyperCVAD in Frontline ALL

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Xiaoli Mi, MD;Varun Narendra, MD

Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Treatment Options After Progression on Frontline Maintenance Therapy

The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Treatment Approaches Using Ruxolitinib in GVHD

Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Additional Approaches for Steroid-Refractory Chronic GVHD

In a discussion on the use of ruxolitinib in GVHD, experts consider the potential role of dose reductions or dose holds to mitigate toxicity and comment on experiences with combining or sequencing therapies in later lines of treatment.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Previous Trials of ctDNA Analysis in Patients With CRC

Expert panelists comment on additional treatment options for significant steroid-refractory chronic GVHD following initial therapeutic intervention, including rechallenging with prophylactic agents or initiating B-cell therapy.

Stacey A. Cohen, MD;Mark Lewis, MD

GALAXY: Disease-Free Survival by Stage and ctDNA Status

Mark Lewis, MD, provides a historical perspective of circulating tumor DNA and discusses previous trials on ctDNA analysis in patients with CRC.

Stacey A. Cohen, MD;Mark Lewis, MD

Transplant-Ineligible Multiple Myeloma: The MAIA Trial

Stacy A. Cohen, MD, and Mark Lewis, MD, comment on disease-free survival rates by ctDNA status in patients enrolled in the GALAXY study.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Case Presentation: An 82-Year-Old Woman with Transplant-Ineligible Multiple Myeloma

An overview of the study design, efficacy, and safety findings of the MAIA trial.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Sequencing Strategies for Renal Cell Carcinoma Treatment Regimens

Dr Nisha Joseph presents the case of a woman with transplant-ineligible multiple myeloma and discusses considerations when choosing frontline treatment regimens.

Thomas E. Hutson, DO, PharmD;Scott S. Tykodi, MD, PhD

Side Effects of IO/TKI Treatment Regimens for Renal Cell Carcinoma

A look at how to best sequence therapies for renal cell carcinoma from the front-line setting on.

Thomas E. Hutson, DO, PharmD

Subcutaneous Treatment of Early-Stage HER2+ Breast Cancer During the COVID-19 Pandemic

Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.

Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injections for Early-Stage HER2+ Breast Cancer

May 11th 2022

Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.